Peptide exosite inhibitors of factor VIIa as anticoagulants

被引:0
|
作者
Mark S. Dennis
Charles Eigenbrot
Nicholas J. Skelton
Mark H. Ultsch
Lydia Santell
Mary A. Dwyer
Mark P. O'Connell
Robert A. Lazarus
机构
[1] Genentech Inc.,Department of Protein Engineering
[2] University of Chicago,Department of Biochemistry and Molecular Biology
来源
Nature | 2000年 / 404卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Potent anticoagulants have been derived by targeting the tissue factor–factor VIIa complex with naive peptide libraries displayed on M13 phage. The peptides specifically block the activation of factor X with a median inhibitory concentration of 1 nM and selectively inhibit tissue-factor-dependent clotting. The peptides do not bind to the active site of factor VIIa; rather, they work by binding to an exosite on the factor VIIa protease domain, and non-competitively inhibit activation of factor X and amidolytic activity. One such peptide (E-76) has a well defined structure in solution determined by NMR spectroscopy that is similar to the X-ray crystal structure when complexed with factor VIIa. These structural and functional studies indicate an allosteric ‘switch’ mechanism of inhibition involving an activation loop of factor VIIa and represent a new framework for developing inhibitors of serine proteases.
引用
收藏
页码:465 / 470
页数:5
相关论文
共 50 条
  • [31] Factor IXa inhibitors as novel anticoagulants
    Howard, Emily L.
    Becker, Kristian C. D.
    Rusconi, Christopher P.
    Becker, Richard C.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (04) : 722 - 727
  • [32] Factor XIa Inhibitors as New Anticoagulants
    Quan, Mimi L.
    Pinto, Donald J. P.
    Smallheer, Joanne M.
    Ewing, William R.
    Rossi, Karen A.
    Luettgen, Joseph M.
    Seiffert, Dietmar A.
    Wexler, Ruth R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (17) : 7425 - 7447
  • [33] Anticoagulants: Thrombin and factor Xa inhibitors
    Fevig, JM
    Wexler, RR
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 34, 1999, 34 : 81 - 100
  • [34] Efforts toward oral bioavailability in factor VIIa inhibitors
    Vijaykumar, Dange
    Rai, Roopa
    Shaghafi, Michael
    Ton, Tony
    Torkelson, Steve
    Leahy, Ellen M.
    Riggs, Jennifer R.
    Hu, Huiyong
    Sprengeler, Paul A.
    Shrader, William D.
    O'Bryan, Colin
    Cabuslay, Ronnell
    Sanford, Ellen
    Gjerstadt, Erik
    Liu, Liang
    Sukbuntherng, Juthamas
    Young, Wendy B.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (14) : 3829 - 3832
  • [35] Discovery methodology for the development of direct factor VIIa inhibitors
    Henry, Brian L.
    Desai, Umesh R.
    EXPERT OPINION ON DRUG DISCOVERY, 2014, 9 (08) : 859 - 872
  • [36] Inhibitors of tissue Factoro•Factor VIIa for anticoagulant therapy
    Lazarus, RA
    Olivero, AG
    Eigenbrot, C
    Kirchhofer, D
    CURRENT MEDICINAL CHEMISTRY, 2004, 11 (17) : 2275 - 2290
  • [37] Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors
    Young, G
    McDaniel, M
    Nugent, DJ
    HAEMOPHILIA, 2005, 11 (03) : 203 - 207
  • [38] Development of factor VIIa inhibitors: Addressing pharmacokinetic parameters
    Kolesnikov, A
    Rai, R
    Young, WB
    Torkelson, S
    Shrader, WD
    Leahy, EM
    Katz, BA
    Sprengeler, PA
    Liu, L
    Mordenti, J
    Gjerstad, E
    Janc, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U153 - U153
  • [39] Discovery and optimization of potent and selective tissue factor/factor VIIa inhibitors
    Hirota, Shinsuke
    Clark, Richard
    Matsuura, Fumiyoshi
    Kira, Kazunobu
    Azuma, Hiroshi
    Nagakura, Tadashi
    Horizoe, Tatsuo
    Tabata, Kimiyo
    Kusano, Kazutomi
    Omae, Takao
    Inoue, Atsushi
    Critchley, David
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [40] Screening for exosite-targeting inhibitors of the anthrax lethal factor metalloproteinase
    Turk, Benjamin E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237